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ABSTRACT 
Failure in O-glycan chain extension exposing Tn antigen (GalNAc-O-Ser/Thr) is clinically associated with cancer 
metastasis. This study provides evidence of a functional role for aberrant GalNAc-glycans in cancer cell capture 
from blood flow and / or adhesion to endothelium. Adhesion of breast cancer cells to human umbilical vein 
endothelial cell monolayers was modelled under sweeping flow. Adhesion of metastatic, GalNAc glycan-rich, 
MCF7 and ZR 75 1 cells to endothelium increased over timepoints up to 1.5 hour, after which it plateaued. 
Adhesion was significantly inhibited (p<0.001) when cell surface GalNAc-glycans were masked, an effect not 
seen in GalNAc glycan-poor, non-metastatic BT 474 cells. Masking irrelevant galactose- and mannose-glycans 
had no inhibitory effect. Imaging of cells post-adhesion over a 24 hour time course using confocal and scanning 
electron microscopy revealed that up to 6 hours post-adhesion, motile, rounded cancer cells featuring 
lamellipodia-like processes crawled on an intact endothelial monolayer. From 6-12 hours post-adhesion, 
cancer cells became stationary, adopted a smooth, circular flattened morphology, and endothelial cells 
retracted from around them leaving cleared zones in which the cancer cells proceeded to form colonies 
through cell division.  
 
Keywords Helix pomatia agglutinin , Tn antigen, glycosylation, metastasis, adhesion 
 
 
 
Abbreviations: GalNAc - N-acetylgalactosamine; HPA - Helix pomatia agglutinin; HUVEC - human umbilical vein 
endothelial cells; PBS - phosphate buffered saline; EDTA - ethylenediaminetetraacetic acid; TNF-alpha - tumour 
necrosis factor-alpha; HPTS - 8-hydroxypyrenetrisulphonic acid; PNA -peanut agglutinin; Con A - concanavalin 
A; SEM - scanning electron microscopy; IL-1 - interleukin-1; IL-6 - interleukin 6; ICAM-1 -intercellular adhesion 
molecule-1; GM1 - monosialotetrahexosylganglioside; MMP9 -  matrix metalloproteinase 9 
 
Running title: GalNAc glycans in cancer cell adhesion     Bapu et al 
3 
 
1. INTRODUCTION 
Altered glycosylation has frequently been reported in cancer cells, and in some instances is associated with 
increased potential for invasion and metastasis (reviewed by [1]). An increase in exposure of N-
acetylgalactosamine (GalNAc) glycans, which can be detected by binding of the lectin from Helix pomatia (HPA, 
Helix pomatia agglutinin), has been reported to be associated in clinical studies with poor patient prognosis 
and metastatic competence in a range of cancers, including those of breast [2-9], oesophagus [10], stomach 
[11,12], colorectum [13], lung [14], prostate [15], thyroid [16] and malignant melanoma [17]. HPA recognises 
heterogeneous O-linked glycans on cancer cells, including, but not exclusively, the cancer-specific Tn-antigen, 
GalNAc-O-Ser/Thr [18], which itself has been consistently reported as being associated with metastasis and 
poor prognosis in several cancer types, and has received interest as a target for vaccine development 
(reviewed by [19,20]).  
 
Although metastasis is the commonest cause of death in cancer patients, owing to its complexity, it remains 
incompletely understood. The metastatically successful cancer cell is rare because it needs to successfully 
accomplish a number of steps, each requiring different behavioural characteristics supported by complex 
molecular signatures. These steps include (1) induction of angiogenesis to support the needs of the growing 
tumour (2) motility and invasion of stroma (3) intravasation into lymphatic system or blood circulatory system 
(4) adhesive interaction with the endothelial lining of blood vessels or lymphatics (5) and extravasation and 
establishment of a new tumour at a distant site (reviewed by [21,22]). It is clearly not possible to study the 
metastatic cascade in human subjects in vivo and animal models have provided some insight into the process, 
although they have well-recognised limitations. The altered GalNAc-glycotype recognised by HPA is associated 
with increased metastatic potential in animal models of several cancer types (eg [23-25]).  In vitro models of 
defined aspects of metastatic mechanisms can be helpful in elucidating parts of the process in detail. 
Previously, we have reported that GalNAc-glycans are not functionally involved in cancer cell adhesion to, or 
invasion through, basement membrane [26]. In the study reported here we investigate the potential functional 
role of GalNAc-glycans in cancer cell adhesive interactions with endothelium during hematogenous 
dissemination. While mechanical entrapment of tumour cells undoubtedly accounts for their arrest in small 
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vessels, there is evidence of specific adhesive interactions between cancer cells and endothelium that 
contributes to the distinctive organ-specific pattern of metastatic spread in many types of cancer [27-30]. 
Thus, we focus on cancer cell interactions with endothelial cells under conditions of sweeping flow mimicking 
that encountered in blood circulation. Assays were performed using the breast cancer epithelial cell lines BT 
474, ZR 75 1 and MCF7. We have previously thoroughly characterised these cells for their synthesis of HPA-
binding glycans of interest [26 ,31,32]. As summarised in Table 1, BT 474 was derived from a primary breast 
cancer and stably synthesises negligible levels of HPA-binding GalNAc glycans. MCF7 and ZR 75 1 were derived 
from breast cancer metastases, are tumorigenic in animal models, and HPA-binding GalNAc glycan-rich. 
Furthermore, they stably synthesise a profile of HPA-binding glycoproteins that is shared by clinical breast 
tumours [26,31] thus validating their use in studies investigating this feature of aberrant glycosylation in 
cancer.   
 
2. MATERIALS & METHODS 
2.1 Cells and cell culture 
BT 474 and ZR 75 1 were obtained from the European Collection of Cell Cultures and MCF7 were a gift from Dr. 
Jostein Dahle (Oslo University, Norway). Human umbilical vein endothelial cells (HUVEC) were obtained from 
Lonza, UK. Details of culture media for each cell type is given in Table 2.  
All assays were performed using breast cancer cells from within five consecutive passages and HUVEC from 
within three passages to minimise phenotypic variation. All plastics were pre-coated in 0.2% w/v bovine 
gelatin (Sigma Aldrich Co. Ltd., UK) in phosphate buffered saline (PBS), pH 7.4. Adherent cell monolayers were 
harvested for passaging and for assays using, for HUVEC, 0.025%-trypsin-0.02% EDTA (Gibco, UK) and for 
breast cancer cell lines 0.05%-trypsin-0.02% EDTA (Gibco, UK). Cultures were maintained under 5% CO2 / air at 
37
o
C . 
 
2.2 Cancer cell-endothelial cell adhesive interactions under conditions of sweeping flow: 
2.2.1 Quantifying MCF7 and ZR 75 1 cancer cell adhesion to endothelial cell monolayers over time 
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HUVEC were grown to confluence in 35mm confocal microscope imaging-compatible ibidi dishes (Thistle 
Scientific, UK) pre-coated in 0.2% v/v bovine gelatin. They were stimulated with 10ng/ml TNF-α (Sigma Aldrich 
Co. Ltd., UK) in EBM-2 media for 2 hours prior to the assay. At the same time, the cells from the cell lines 
originally derived from breast cancer metastases, MCF7 and ZR 75 1, were labelled overnight prior to the assay 
in 10mg/ml solution of fluorescent 8-hydroxypyrenetrisulphonic acid (HPTS; Sigma Aldrich Co. Ltd., UK).  
Unincorporated HPTS was aspirated and the cells washed in 5 changes of PBS before trypsinising, as described 
previously, to obtain a cell suspension. 1ml of cell suspension containing 2x10
5
 HPTS-labelled breast cancer 
cells was introduced to each HUVEC monolayer and the dishes rocked gently on a platform with a north-south 
/ east-west rocking motion for time periods of 5 mins; 15 mins; 30 mins; 45 mins; 1 hr; 1.5 hr and 2 hr. At the 
end of the rocking period, the HUVEC monolayer was gently washed in 3 changes of PBS to remove any non-
adherent breast cancer cells and imaged using a Zeiss confocal microscope using a 10x plan Neofluar objective 
and 458nm laser and 475 LP filter. Two technical replicates and three biological replicates were performed for 
each assay.  For each assay dish, 15 randomly chosen images were captured, giving a total of 90 images per 
time point for each cell line. Adherent HPTS-labelled cancer cells were enumerated. 
2.2.2 Exploring the effect of masking cancer cell surface glycans on MCF7, ZR 75 1 and BT 474 cancer cell 
adhesion to endothelium 
To determine the effect of masking cell surface GalNAc-glycans on cancer cell adhesion to endothelial cell 
monolayers, BT 474, ZR 75 1 and MCF7 cancer cell suspensions were prepared and HPTS-labelled as described 
previously then incubated with 10µg/ml solution of the GalNAc-binding lectin HPA.  In order to control for the 
potential effect of steric hindrance from the relatively large HPA molecule, as well as for the effects of blocking 
GalNAc-glycans specifically, cells were also incubated with peanut agglutinin (PNA) or concanavalin A (Con A) 
(all from Sigma Aldrich Co. Ltd., UK) in culture medium, or incubated with culture medium alone (positive 
control), for 2 hours to achieve lectin binding to the cells. The carbohydrate-binding preferences of the lectins 
are summarised in Table 3. Cells were washed thoroughly to remove unbound lectin before proceeding. 1ml of 
cell suspension containing 2x10
5
 HPTS-labelled cells were then applied to a HUVEC monolayer and the dishes 
rocked gently, as described previously,  for 1.5 hr. Each test consisted of 4 dishes, one each for positive control 
(no lectin), plus HPA, PNA and Con A groups, and three technical replicates of each were performed. Images of 
20 randomly chosen fields were captured per dish, totalling 60 images per group for each cell line tested.  
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Adherent HPTS-labelled cancer cells were enumerated and the number of adherent cancer cells in the positive 
control (no lectin masking) in comparison to HPA, PNA and Con A glycan-masking groups were analysed.  
Data were analysed using a Shapiro-Wilks test for normal distribution. A T-test was applied to normally 
distributed data and a non-parametric Wilcoxon signed ranks test was applied to data that was not normally 
distributed. p values of <0.05 were considered to be statistically significant.  
 
2.3 Imaging post-adhesion MCF7 cancer cell behaviour 
2.3.1 24 hr time course, live cell imaging 
Confluent HUVEC monolayers were established in a 6-well confocal microscope-compatible plate (Wafergen 
Biosystems UK ‘smartslide system’). HPTS-labelled MCF7 cells, were introduced on the endothelial cell 
monolayer and allowed to interact under conditions of sweeping flow, for 1.5 hr, as described previously. Non-
adherent cells were removed by gentle washing in 3 changes of PBS and then 5mls of fresh EBM 2 media was 
added. The plate was introduced into a micro-incubator system (Wafergen Biosystems UK ‘smartslide system’) 
mounted on the stage of Zeiss confocal microscope and cells maintained at 37
0
c in 5% CO2 / air. A single, 
representative field of view was selected and cells were imaged using a 10x plan Neofluar objective and 
458nm laser and 475 LP filter every 5 mins for 24 hr.   
 
2.3.2 24 hr time course imaged using scanning electron microscopy 
Confluent HUVEC monlayers were established on plastic coverslips placed within 24 well plates. Unlabelled 
MCF7 cells were introduced on the endothelial cell monolayer and allowed to interact under conditions of 
sweeping flow, for 1.5 hr, as described previously. Non-adherent cells were removed by gentle washing in 3 
changes of PBS and then 5mls of fresh EBM 2 media was added. The plates were then returned to a 37
0
c 
incubator and maintained under 5% CO2 / air. Coverslips were removed at time points: 30 mins, 1 hr, 2 hr, 6 hr, 
12 hr and 24 hr and processed for imaging for scanning electron microscopy (SEM) as follows. Cells were fixed 
with 2% v/v glutaraldehyde (TAAB, U.K) and 2% v/v paraformaldehyde (Agar Scientific) in 0.1M sodium 
cacodylate buffer (Agar Scientific) at pH 7.4 for 1 hr. They were then washed in 1M sodium cacodylate buffer, 
Running title: GalNAc glycans in cancer cell adhesion     Bapu et al 
7 
 
then incubated in 1% v/v osmium tetroxide (Agar Scientific) in distilled water for 1 hr. Cells were then washed 
three times in 1M sodium cacodylate buffer to remove excess osmium tetroxide. They were then dehydrated 
through a series of graded ethanol solutions and dried in a critical point dryer (Tousimis, Samdri-780). They 
were sputter coated with gold using a conductive metallic sputter coater (Agar auto sputter coater) and 
imaged using a Hitachi 3400N scanning electron microscope.  
 
3. RESULTS 
3.1 Cancer cell-endothelial cell adhesive interactions under conditions of sweeping flow: 
3.1.1 Quantifying MCF7 and ZR 75 1 cancer cell adhesion to endothelial cell monolayers over time 
 
Adhesion of MCF7 and ZR 75 1 cells, originally derived from cancer metastases, to endothelial monolayers 
under conditions of gentle sweeping flow was quantified over time. Results are summarised in Table 4 and 
illustrated in Figure 1.  There was minimal adhesion of cancer cells to endothelial monolayers at early time 
points, 5-15 min, but numbers of adherent cancer cells gradually increased from 30 min until the 1 hr 30min 
time point after which no further increase in numbers of adherent cells was seen. The endothelial monolayer 
remained intact over this time frame with no evidence of cell loss, damage or detachment.  
 
3.1.2 Exploring the effect of masking cancer cell surface glycans on MCF7, ZR 75 1 and BT 474 cancer cell 
adhesion to endothelium 
 
Physically masking the GalNAc glycans by pre-incubation of the cells with HPA resulted in a significant decrease 
in the adhesion of GalNAc glycan-rich MCF7 and ZR 75 1 cancer cells to the endothelial cell monolayer 
(p<0.0001). Pre-incubating the GalNAc glycan-poor BT 474 cells with HPA had, predictably, no significant effect 
on their adhesion. Moreover, pre-incubation of the three cell lines with PNA to mask galactose-glycans or Con 
A to mask mannose-glycans, and the steric effect of their presence, had no significant effect on cell adhesion. 
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These results are summarised in Table 5 and illustrated in Figure 2. Pre-incubation of the cells with lectins had 
no detectable adverse effects on their viability or morphology (data not shown). 
 
3.2 Imaging post-adhesion MCF7 cancer cell behaviour 
3.2.1 24 hr time course, live cell imaging 
Live cell imaging of cancer cell interactions with endothelial monolayers for up to 24 hr post-adhesion revealed 
that at early time points, up to 12 hr post adhesion, the adherent cancer cells exhibited a rounded morphology 
and were motile, moving on the endothelial monolayer. Towards the end of this 12 hr time frame, cancer cells 
settled, ceased to move, and their morphology changed to a markedly flattened appearance. During the time 
frame 12-24 hr post-adhesion, endothelial cells retracted away from the adherent, now stationary cancer cells, 
forming a cleared zone. Cancer cells then proceeded to undergo cell division within the cleared zone forming 
small colonies by the end of the imaging period. These observations are illustrated in Figure 3 and in Movie 1. 
(for print version the last sentence of the above paragraph should read ‘These observations are illustrated in 
Figure 3’) 
3.2.2 24 hr time course imaged using scanning electron microscopy 
Observations recorded using live cell imaging were supported by SEM. At early time points (1-6 hr), adherent 
cancer cells were roughly spherical but many exhibited processes resembling lamellipodia consistent with their 
crawling along the endothelial monolayer. The endothelial monolayer resembled an unbroken and continuous 
pavement (Figure 4A and B). By 6-12 hr post-adhesion, endothelial cells had begun to retract from the cancer 
cells forming a cleared zone from around them (Figure 4 C and D). Cancer cells adopted a circular, flattened 
morphology with minimal evidence of cell processes (Figure 4D). By 12 hr post-adhesion, cancer cells had 
settled into the cleared areas are cell division was imaged (Figure 4E). Transcellular migration was also imaged 
(Figure 4F).  
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4.  DISCUSSION 
In the study reported here, we employed an assay involving sweeping flow to model interactions where cancer 
cells are moving in the blood stream.  This type of assay is commonly used to investigate the interactions 
between leukocytes and endothelial monolayers during the inflammatory response, which has frequently been 
proposed as a paradigm of cancer cell adhesion and extravasation during metastasis. A rocking platform with a 
north-south/east-west direction of motion avoided vortices that are induced by circular rocking motion. Prior 
to the assays, the endothelial cells were stimulated with TNF-α as we have previously demonstrated that this 
increases the rates of cancer cells adhesion to endothelial cells markedly, indicating that molecules that are 
up-regulated by TNF-α may be involved in adhesive interactions [25]. 
 
Initial time series experiments indicated that there was little cancer cell adhesion to the endothelial monolayer 
at early time points, up to 30 mins. From 30 mins to 1 hr 30mins, adhesion increased steadily, then plateaued. 
The endothelial monolayer remained intact and apparently undamaged during the course of the assays. 
Mechano-stimulation of the endothelial cells by the sweeping flow may contribute to the gradual increase in 
cell adhesion as shear forces of flow have been demonstrated to up-regulate molecules potentially involved in 
cancer cell-endothelial cell interaction and adhesion, including IL-1 and IL-6, and mediate adhesive behaviour 
[30]. It has also been reported that ICAM-1 expression is induced by shear stress in HUVEC monolayers [42]. 
There was no significant further adhesion after 1hr 30 mins and prolonged assays under flow resulted in the 
endothelial monolayer becoming damaged and detached (data not shown).  
 
Masking exposed GalNAc-glycans by pre-incubating cancer cells with the GalNAc-binding lectin HPA had a 
marked significant inhibitory effect on the MCF7 and ZR 75 1 cells’ ability to adhere to the endothelial 
monolayers under conditions of flow. Unsurprisingly, no inhibitory effect was seen after pre-incubating the 
GalNAc-glycan poor BT 474 cells. Masking of, in this context, irrelevant (ie non-GalNAc-) galactose- and 
mannose-glycans by lectins PNA and Con A, respectively, also had no inhibitory effect, even though both 
lectins recognise binding partners on breast cancer cells which have, like HPA, been reported to have some 
prognostic significance (eg [43-47]).  Moreover, that the observed inhibition in cancer cell adhesion to 
endothelium was as a result of specifically masking GalNAc-glycans, and not of steric hindrance in the presence 
bound HPA, is exemplified by the lack of inhibition in the presence of either bound PNA or Con A. The 
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hexameric (actually, a non-covalent trimer of covalent dimers) HPA molecule has a reported molecular weight 
of 79 kDa, although it occurs in different glycoforms with slightly variable molecular weights [36,48]. Molecular 
weights of PNA and Con A are comparable to this. The tetrameric PNA molecule has a molecular weight of 
100.8 kDa [49]. There has been controversy in the literature as to the molecular weight of Con A, but at the pH 
employed in the experiments reported here, it is reported to exist as a mixture of monomers of molecular 
weight 53kDa and also dimers composed of these subunits [50]. In addition to the evidence reported here 
supporting a functional role for GalNAc-glycans in cancer cell adhesion to endothelium, inhibition of adhesion 
of GalNAc-rich cancer cells to endothelial monolayers was also observed in the presence of free GalNAc. 
However, the presence of monosaccharide had a detrimental effect on the endothelial monolayer, causing it 
to become partially detached from the plasticware and thus rendering analysis unreliable (data not shown) 
and further optimisation of the assay, resulting in the approach reported, here was therefore necessary.  
 
These data, therefore, are consistent with HPA-binding GalNAc-glycans having a functional role in cancer cell 
adhesion to endothelium, although the GalNAc glycan-poor BT 474 cells were also able to adhere to 
endothelial monolayers, presumably through alternative mechanisms. While both HPA-binding and detection 
of Tn antigen have been much reported in the literature to be associated with aggressive biological behaviour 
and poor patient prognosis in a range of cancer types, as described previously, the functional reason for this 
has not previously been apparent. Intriguingly, the results presented here are consistent with a report [19] of 
an anti-Tn monoclonal antibody not only specifically recognising Tn antigen on cancer cells, including MCF7 cell 
tumours in a mouse model, but also inhibiting adhesion of MCF7 cells to lymphatic endothelial cells, thus 
functionally implicating GalNAc-glycans in lymphatic as well as blood-borne dissemination.  
 
While there is ample evidence that cancer cells become physically trapped in small-bore capillaries during 
hematogenous dissemination (eg [51,52]), capture of cancer cells from blood flow also contributes to 
metastatic mechanisms [27-30], as modelled here. This process has been shown to involve similar adhesive 
interactions as those involved in the well-studied leukocyte capture from blood flow. In leukocyte adhesion to 
endothelium under conditions of flow, there is initial recognition of glycan Lewis a and Lewis x antigens by E-
selectin expressed by activated endothelial cells (reviewed by [53]). There is no evidence that GalNAc-glycans 
can act as binding partners for selectins. Indeed, we have observed that while cancer cells are able to roll on 
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both HUVEC monolayers and recombinant E-selectin, but not P-selectin, coated microslides in a manner 
reminiscent of that of leukocytes, this behaviour is not inhibited by blocking the exposure of GalNAc glycans 
(unpublished observation). Moreover, there is evidence confirming this in a scid mouse colorectal cancer 
model [54]. Here, the labelling distribution of HPA for GalNAc-glycans and of selectins to the cancer cells, while 
somewhat overlapping, were distinct and, possibly, complementary. It seems likely, therefore, that the GalNAc 
glycans are functionally implicated in later, firm adhesion once initial selectin-mediated tethering has been 
achieved, or under circumstances where cancer cells are slowed or trapped in vessels and come into close 
contact with the endothelial wall.  In the assay system employed in the current study, while the cancer cells 
were subject to constant sweeping flow, they also had an extended time period in which to interact with the 
endothelial monolayer with which they would inevitably come into repeated, close contact. While there has 
been greater focus on T-antigen and sialyl-T antigen than on Tn antigen in this context, it has been reported 
that cancer-associated truncated O-linked glycan structures like these promote metastasis through their 
recognition by galectin-3 expressed on other cancer cells, thereby causing homotypic aggregation of cancer 
cells and thus promoting metastasis, or on endothelial cells thus facilitating adhesion to endothelium [55-57], 
thus exemplifying the potential role of glycan recognition in metastatic mechanisms. Intriguingly, the galectin-
3 is also reported to regulate accumulation of GM1 and N-cadherin at cell-cell junctions, thus destabilising 
them and promoting cancer cell migration [58]. Integrins appear to be key players in the development of the 
later, stable and firm adhesive attachments [59] and here an increase in the synthesis of trimeric Tn antigen on 
syndecan 1 in complex with alpha 5 beta 1 integrin and MMP9 has recently been demonstrated to enhance 
invasion and metastasis in a murine Lewis lung cancer model [60], consistent with GalNAc-glycans functioning 
here.  
 
Imaging events over a 24 hr post-adhesion time course using both live cell imaging and SEM revealed that, 
initially, cancer cells exhibiting a rounded morphology crawled on the endothelial monolayer by extending 
cellular processes. Recently it has been demonstrated that in cells where Tn antigen density was increased by 
relocating the relevant glycosyltransferases to the endoplasmic reticulum rather than Golgi apparatus, Tn 
antigen density was especially enhanced in the lamellipodia [61]. This was associated with enhanced motility 
and invasiveness. Thus, in addition to a putative functional role in cancer cell capture from blood flow and  / or 
securing cancer cell adhesion to the endothelium, GalNAc glycans may also function in cancer cell crawling on 
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the endothelial monolayer and subsequent invasion into local tissues. In the study reported here, after 
crawling on the endothelial monolayer, from around 6 hr, cells became stationary and the endothelial cells 
around them retracted to form clear zones. Evidence of transcellular migration was also seen. This behaviour is 
entirely consistent with that reported in leukocytes during transendothelial migration. Here, after leukocytes 
are captured from circulation, they migrate to endothelial cell borders and, through interaction of a 
bewildering array of signalling molecules, well reviewed, for example, by [62,63], cause the endothelial cells to 
retract facilitating diapedesis. There has also been much interest in transcellular migration of leukocytes 
through endothelia (eg [64,65]).  Clearly, the similarities between leukocyte and cancer cell capture and 
transmigration are striking. However, leukocyte capture from blood flow and subsequent diapedesis is rapid, 
taking less than 1 min. Here, once cancer cells were adherent to endothelium, their movement over the 
endothelial monolayer and eventual retraction of endothelial cells took place over a longer time scale, 
reflecting the cancer cells limited ability to mobilise the same molecular players. These observations are in 
accordance with the studies reporting in detail the steps, and chronology, in arrest and extravasation of 
several cancer cell lines in an in vivo mouse model [51,52].  Tumour cells arrested in vessels and remained, 
within a platelet thrombus, in close contact with the vessel wall for 8-24 hr before the endothelial cells 
retracted to facilitate their firmer and stable attachment to subendothelial matrix.  In the study reported here, 
from 6-12 hr, cancer cell division was observed such that small cancer cell colonies were formed. This is 
consistent with observations [51,52 and references therein] of cell division after 4-24 hr following arrest in the 
capillaries, depending on cancer cell type. There is strong evidence that metastases arise as a result of such 
intravascular proliferation of cancer cells adherent to endothelium even without active extravasation [66]. 
Cancer cell proliferation within the lumen of the capillary eventually results in it disruption and cancer invasion 
of local tissues. Thus, while the simple assay system employed here is limited in that it was not designed to 
model extravasation and invasion through extracellular matrix, its relevance in exploring cancer cell-
endothelial cell molecular interactions remains. 
 
While metastasis is a complex multi-step cascade of events, the focus of this study, that of cancer cell arrest 
within blood vessels and subsequent transendothelial  migration to form tumour cell colonies at a new site is 
of special interest.  The study reported here provides evidence for the first time that altered glycosylation, 
featuring GalNAc-glycans including the Tn antigen, repeatedly reported to be associated with metastasis and 
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poor prognosis in a range of cancers, function in specific adhesive interactions between cancer cells and 
endothelium. 
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Figure 1. (A) MCF7 and (B) ZR 75 1 cancer cells (green) adhering to the endothelial cell layer at 
various times after seeding (5, 30, 60 and 90 mins). Scale bar = 250µm. (C) Number ± SEM of 
adherent MCF7 (blue solid line) and ZR 75 1 (red dashed line) cells to the endothelial cell layer over 
time. 
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Figure 2. The effect of masking surface glycans on MCF7 (blue horizontally striped bars), ZR 75 1 (red 
checkerboard bars) and BT 474 (green vertically striped bars) cancer cell adhesion to endothelium. 
Mean ± SEM numbers of adherent MCF7, ZR 75 1, and BT 474  cells to endothelial cell layer after 
GalNAc glycans are masked by HPA, galactose glycans are masked by PNA, mannose glycans are 
masked by ConA, or with no lectin masking (control). Masking GalNAc glycans by HPA significantly 
reduces MCF7 and ZR 75 1 cancer cell adhesion to endothelium relative to controls of the same cell 
type and relative  to glycan masking using PNA or ConA (*** p<0.001). 
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Figure 3. Confocal microscopy live cell imaging timelapse of MCF7 cancer cells (green) interacting 
with endothelial cell monolayer. MCF7 cancer cells were allowed to adhere to the endothelial cell 
monolayer under conditions of sweeping flow for 1.5 hr. Then, non-adherent cells were eluted and 
adherent cells imaged for up to 24hr. The arrowhead marks progress of a single cell during the time 
course. At early time points, up to 12 hr, cancer cells were motile. Note position of arrowed cell 
moving from 2 hr, to 6 hr, to 12 hr. From 12 hr, cancer cells settled, lost their motility and flattened. 
Note the change in the morphology of the arrowed cancer cell at 12 hr.  By 24 hr, endothelial cells 
have retracted away from stationary cancer cells, leaving a cleared zone, and cancer cells begin to 
undergo cell division. Scale bar = 50µm. 
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Figure 4. Scanning electron micrography timelapse of MCF7 cancer cells (red) interacting with 
endothelial cell monolayer. MCF7 cancer cells were allowed to adhere to the endothelial cell 
monolayer under conditions of sweeping flow for 1.5 hr. Then, non-adherent cells were eluted and 
adherent cells imaged at time points up to 24 hr later.  A) 1 hr. Cancer cells are adherent to a 
continuous endothelial monolayer and exhibit a rounded morphology a rounded appearance. B) 2 
hr. Cancer cells extend processes  consistent with their crawling on the endothelial monolayer. C) 6 
hr.  Endothelial cells have retracted from around cancer cells leaving a cleared zone. D) 12 hr. Cancer 
cells are flattened and adherent in the gap between retracted endothelial cells. E) 12 hr Cancer cell 
division within cleared areas in the endothelial monolayer. F) Transcellular migration. Scale bar 
panels A, and C-f = 25µm. Scale bar B = 10µm. 
Table 1 Derivation and level of synthesis of aberrant GalNAc-glycans of cell lines employed in this study 
 
Cell line  Derivation & description       Synthesis of aberrant GalNAc-glycans* 
 
 
BT 474  Derived from a primary, invasive, ductal carcinoma of the breast [33]  Negligible [26,31] 
 
 
ZR 751  Derived from malignant ascites arising from a primary invasive ductal   Moderately strong. Expresses  a heterogeneous profile of  
carcinoma. Tumorigenic in nude mice in the presence of oestrogen [34]. HPA-binding glycoproteins shared by human clinical 
tumour samples**[26,31] 
 
MCF7  Derived from malignant pleural effusion arising from a primary invasive   Very strong.  Expresses  a heterogeneous 
ductal carcinoma. Oestrogen receptor positive. Tumorigenic in nude   profile of HPA-binding glycoproteins shared by human  
mice; tumorigenic and metastatic in scid mice models [35]   clinical tumour samples**[25,26,31] 
 
*as assessed by HPA binding profile based on lectin histochemistry & flow cytometry. ** as assessed by Western blot 
 
Table 2 Cell culture media 
 
Cell type Culture media    Supplements 
 
BT 474 IMDM media (PAA, UK)   10%  v/v heat inactivated fetal calf serum (Sigma Aldrich Co. Ltd., UK),  2mM L-glutamine (Gibco,  
UK), 1% v/v streptomycin and penicillin (Sigma Aldrich Co. Ltd., UK). 
 
ZR 75 1  RPMI-1640 media (Gibco, UK)  as BT 474 
 
MCF7   DMEM:F-12 media (Gibco, UK)  as BT 474 
 
HUVEC   EBM-2 media (Clonetics, Lonza, UK)  Supplement pack (Clonetics, Lonza, UK) contains: hydrocortisone, human fibroblast derived growth  
       factor, vascular endothelial growth factor, R3-insulin derived growth factor, ascorbic acid, heparin,  
       human epidermal growth factor, fetal calf serum and gentamycin and amphotericin  
 
Table 3 Lectin carbohydrate-binding partners 
 
Lectin      Carbohydrate binding partners 
HPA (Helix pomatia agglutinin)   GalNAc-α-1,3GalNAc; α-GalNAc; α-GlcNAc [36,37] 
PNA (Peanut agglutinin)    Gal(Β13)GalNAc; D-Gal; Gal(Β13)GalNAc-Ser/Thr (T antigen)[38,39] 
Con A (concanavalin A)    α-mannose; glucose; trimannosyl core of N-glycans [40,41] 
Table 4 Quantification of (a)  MCF7 and (b) ZR 75 1 cells  adherent to HUVEC over time 
 
Time points   5 min  15 min  30 min  45 min  1 hr  1.5 hr  2 hr 
 
(a) MCF7 cells 
Total no. adherent cells  440  878  2524  2556  2937  3689  3706 
Mean no adherent cells  5  10  28  28  33  41  41 
/ field of view (n=90)
 1
 
Standard deviation  4.60  6.47  17.22  12.62  16.14  27.95  17.72 
Standard error of the mean 0.48  0.68  1.82  1.33  1.70  2.95  1.87 
 
(b) ZR 75 1 cells 
Total no. adherent cells  479   838  1921  2325  2392  2827  2846 
Mean no adherent cells  5  9  21  26  27  31  32 
/ field of view (n=90)* 
Standard deviation  4.24  8.85  17.19  10.85  10.19  16.33  9.94 
Standard error of the mean 0.45  0.93  1.81  1.14  1.07  1.72  1.05 
 
1
Two technical replicates and three biological replicates were performed for each assay.  For each assay dish, 15 randomly chosen images were captured, 
giving a total of 90 images per time point for each cell line 
 
Table 5. Adhesion of MCF 7, ZR 75 1 and BT 747 cells to HUVEC monolayer after masking glycans using HPA, PNA and Con A  
Cell line   MCF7     ZR 75 1        BT 474 
 
Group   Cont HPA PNA Con A  Cont HPA PNA Con A    Cont HPA PNA Con A 
Total number of  3019 1610 2858 2893  1380 763 1348 1418  1343 1281 1325 1323 
adherent cancer cells 
Mean no. adherent  50 27 48 48  23 13 22 24  22 21 22 22 
cells / field of view  
(n=60
1
) 
Standard deviation 15.72 9.01 20.04 20.81  8.04 7.44 15.56 12.12  11.28 9.23 10.12 12.14 
Standard error of  2.03 1.16 2.59 2.69  1.04 0.96 2.01 1.56  1.46 1.19 1.31 1.57 
the mean 
p value
2
  N/A     <0.0001 0.17 0.38  N/A    <0.0001  0.11 0.69    N/A    0.75 0.91 0.73 
 
Cont: Control group with no lectin masking.  
 1
three technical replicates of each group were performed. Images of 20 randomly chosen fields were captured per dish, totalling 60 images per group for 
each cell line tested 
2
control in comparison to HPA, PNA and Con A glycan-masking groups 
 
 
